bioAffinity Technologies Stockholders Approve Charter Amendment Reducing Authorized Shares to 200 Million
bioAffinity Technologies held a Special Meeting on November 20, 2026 where stockholders approved five proposals, including a charter amendment to decrease authorized common shares from 350,000,000 to 200,000,000 shares. The meeting also approved warrant exercise proposals related to private placement offerings that closed in August and October 2026, as well as an offering proposal for non-public offerings under Nasdaq Marketplace Rule 5635(d).
Key takeaways
Charter amendment: Authorized common shares decreased from 350,000,000 to 200,000,000 shares, effective November 20, 2026
August warrant exercise proposal approved: Up to 1,128,272 shares issuable upon exercise of warrants from August 14, 2026 private placement
October warrant exercise proposal approved: Up to 980,072 shares issuable upon exercise of warrants from October 8, 2026 private placement
Offering proposal approved: Issuance of securities in one or more non-public offerings under Nasdaq Rule 5635(d)
Adjournment proposal approved but not needed as all other proposals passed
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BIAF in real time
Get material earnings, filing, IR, and earnings-call alerts by email.